Sodium Monofluorophosphate

Summary

Sodium Monofluorophosphate (CHEMBL1908359) is an approved small-molecule antibacterial agent (ATC A12CD02); indicated across 5 conditions including dental caries and gingivitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A12CD02 (+1 more)
• Indications: 5 conditions
• Clinical trials: 17
• Chemistry: 143.95 Da · FNa2O3P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908359
Name	Sodium Monofluorophosphate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24266
ChEBI	CHEBI:86431
ATC	A12CD02, A01AA02
Molecular formula	FNa2O3P
Molecular weight	143.95
InChIKey	BFDWBSRJQZPEEB-UHFFFAOYSA-L

SMILES: [O-]P(=O)([O-])F.[Na+].[Na+]

IUPAC name: disodium;fluoro-dioxido-oxo-lambda5-phosphane

ChEBI definition: Sodium fluorophosphate, commonly abbreviated MFP, is an inorganic compound with the chemical formula Na2PO3F. Typical for a salt, MFP is odourless, colourless, and water-soluble. This salt is an ingredient in toothpastes.

Pharmacological roles (ChEBI): antibacterial agent.

Also known as: Extra-strength aim, Mono-tridin, NSC-248, Sodium fluorophosphate, Sodium monofluorophosphate, SODIUM MONOFLUOROPHOSPHATE

Patent coverage: 6,064 distinct patent families (18,059 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
dental caries	4	MONDO:0005276	EFO:0003819
gingivitis	4	MONDO:0002508	MONDO:0002508
periodontitis	4	MONDO:0005076	EFO:0000649
gingival disorder	4	MONDO:0002021	MONDO:0002635

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
allergic disease	2	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE3	8
Not specified	7
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02731833	PHASE4	COMPLETED	Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
NCT02923895	PHASE4	COMPLETED	To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH)
NCT00759031	PHASE3	COMPLETED	Investigation of Dental Plaque and Gingival Index
NCT01005966	PHASE3	COMPLETED	In Situ Caries Model of Fluoride Toothpastes
NCT01592851	PHASE3	COMPLETED	Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
NCT01592864	PHASE3	COMPLETED	The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity
NCT01827670	PHASE3	COMPLETED	Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity
NCT02832375	PHASE3	COMPLETED	Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
NCT03072719	PHASE3	COMPLETED	The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity
NCT04123665	PHASE3	COMPLETED	A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
NCT02371616	Not specified	COMPLETED	Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity
NCT02750943	Not specified	COMPLETED	Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease
NCT02768194	Not specified	COMPLETED	Dentine Tubule Occlusion Assessment in a Modified in Situ Model
NCT02924350	Not specified	COMPLETED	The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH)
NCT02937636	Not specified	COMPLETED	To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population
NCT03160703	Not specified	COMPLETED	Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
NCT06197555	Not specified	COMPLETED	Comparision of the Clinical Efficacy of Different Desensitizing Toothpastes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).